In an APC member survey conducted last month, 59% of compounders said they were not aware that FDA’s Guidance for Industry #256 is slated to be enforced beginning October 1, 2022.
Earlier this week, APC submitted a letter signed by nearly 2,000 prescribers of compounded hormones to FDA Commissioner Robert Califf, urging FDA to assure continued patient access to compounded hormone therapy.
FDA’s director of the Office of Compounding Quality and Compliance, Gail Bormel, has accepted APC’s invitation to attend Compounders on Capitol Hill.
Help us help YOU get ready for GFI #256 by taking a quick survey.
A letter signed by 1,957 prescribers of compounded hormones was submitted this week to FDA Commissioner Robert Califf urging that he preserve continued patient access to compounded hormone therapy.
Maybe you’ve heard about FDA’s GFI 256, regarding animal compounding, and wondered if it might affect mew.
Please take our survey regarding GFI 256.
Here are five compelling reasons you should join us in DC next month...
3,222 folks have sent 9,370 cBHT messages to 269 members of Congress.
Yesterday, APC’s cBHT Campaign Steering Committee hosted an emergency briefing for APC members and compounding supporters and made three urgent asks of them.
FOLLOW US
